Phenylephrine Injectable Recalled Due to Manufacturing Quality Control Deviations
Olympia Compounding Pharmacy is recalling 4,521 vials of Phenylephrine 1 mg/mL due to manufacturing quality control failures. Environmental and personnel monitoring procedures were not properly investigated prior to October 1, 2021.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: The recall addresses Current Good Manufacturing Practice (CGMP) deviations in a compounding pharmaceutical facility, which constitutes a risk-of-harm situation. However, no illnesses, injuries, or deaths have been reported in the source material, limiting the severity to High rather than Severe.
Plain-English summary
Olympia Compounding Pharmacy is recalling 4,521 vials of Phenylephrine 1 mg/mL (NDC 73198-0021-05, Lot H47030, Beyond Use Date 8/30/2022) that were distributed nationwide. This is a prescription multi-dose injectable medication prepared by a compounding pharmacy.
The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations. Prior to October 1, 2021, the pharmacy failed to properly investigate excursions in environmental and personnel monitoring procedures that exceeded Out of Action Limits (OOAL). These monitoring failures raise concerns about potential manufacturing defects.
The recalled product
- Product
- Phenylephrine 1 mg/mL, 5 mL Multi-Dose vial, Rx Only, Olympia Pharmaceuticals 6700 Convoy Rd., Ste. 155, Orlando, FL 32835. NDC 73198-0021-05.
- Manufacturer
- Olympia Compounding Pharmacy dba Olympia Pharmacy
- Hazard
- manufacturing-defect
- quality-control-failure
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Lot: H47030 BUD: 8/30/2022
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27